← Issue №10/ week of Sep 6, 2026/ the whole section, in full

Nutrition, in full.

All 2 Nutrition papers in this issue, as full cards, ranked by clinical utility. The issue page carries the strongest few; this is the section, whole.

Sections this issue
Filter

All 2, in full

most clinically useful first · the 1 the issue led with is ruled in green
Nutrition rct · n=163 · Sep 3, 2026 · Clin Gastro Hep · IF 16.2

STARS Phase 3 Trial: Once-Weekly Apraglutide Reduces Parenteral Support in Short Bowel Syndrome-Intestinal Failure.

New therapyshort bowel syndromeparenteral nutritionenteral nutrition
Clinical takeawayConsider once-weekly subcutaneous apraglutide for SBS-IF patients, particularly those with stoma anatomy, to reduce PS dependence, noting its favorable safety profile.
What it foundApraglutide significantly reduced weekly PS volume by 25.5% vs 12.5% with placebo at 24 weeks in SBS-IF patients, with a greater effect in the stoma subgroup (-25.6% vs -7.8%).
ContextConfirms and extends phase 2 findings, showing apraglutide's efficacy in reducing PS requirements in a larger, global phase 3 trial.
Refinessuggested applicable standard· ESPEN (European Society for Clinical Nutrition and Metabolism), "ESPEN guideline on chronic intestinal failure in adults, Update 2023," Clinical Nutrition, 2023

Decision at stakeconsidering GLP-2 analogs to reduce parenteral support in SBS-IF

… In carefully selected PN-dependent patients, and only when prescribed by clinicians experienced in SBS/IF management (generally once the adaptation phase is complete), consider the GLP-2 analog teduglutide (0.05 mg/kg/day subcutaneously) to promote intestinal adaptation and reduce PN volume, but only after baseline screening to exclude neoplasia and contraindications (colonoscopy with removal of any polyps when colon and/or rectum is present, and assessment for active or recent [within 5 years] gastrointestinal, hepatobiliary, or pancreatic malignancy, which contraindicate its use) and with mandatory ongoing safety monitoring (surveillance colonoscopy after 1-2 years then every 5 years, plus vigilance for colorectal/GI polyps and neoplasia, intestinal obstruction, biliary/gallbladder and pancreatic disease, and fluid overload); add antimotility agents (loperamide, then codeine/opium tincture) for high-output stoma, and provide lifelong nutrient surveillance/supplementation (notably B12) plus monitoring for CRBSI, IFALD, oxalate stones, and refeeding syndrome.

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

Manage short bowel syndrome / intestinal failure with a multidisciplinary IF team using a three-phase nutrition strategy: initiate TPN with IV hydration and electrolyte replacement in the acute hypersecretory phase, progressively advance enteral feeds and wean PN during the 1-2 year adaptation phase, then maintain an oral diet with selective PN as needed. In carefully selected PN-dependent patients, and only when prescribed by clinicians experienced in SBS/IF management (generally once the adaptation phase is complete), consider the GLP-2 analog teduglutide (0.05 mg/kg/day subcutaneously) to promote intestinal adaptation and reduce PN volume, but only after baseline screening to exclude neoplasia and contraindications (colonoscopy with removal of any polyps when colon and/or rectum is present, and assessment for active or recent [within 5 years] gastrointestinal, hepatobiliary, or pancreatic malignancy, which contraindicate its use) and with mandatory ongoing safety monitoring (surveillance colonoscopy after 1-2 years then every 5 years, plus vigilance for colorectal/GI polyps and neoplasia, intestinal obstruction, biliary/gallbladder and pancreatic disease, and fluid overload); add antimotility agents (loperamide, then codeine/opium tincture) for high-output stoma, and provide lifelong nutrient surveillance/supplementation (notably B12) plus monitoring for CRBSI, IFALD, oxalate stones, and refeeding syndrome.

ESPEN (European Society for Clinical Nutrition and Metabolism), "ESPEN guideline on chronic intestinal failure in adults, Update 2023," Clinical Nutrition, 2023 · reviewed 2026-07-23 ↗
Joly F … STARS Investigators · Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association · IF 16.2 · PubMed ↗Permalink
Nutrition prospective cohort · n=758 · Sep 1, 2026 · Am J Clin Nutrition · IF 6.5

Serum-based biomarker development for dietary macronutrient densities and their association with breast and colorectal cancer risk in a cohort of postmenopausal females.

New evidencebiomarkerepidemiologybasic sciencediet therapy
Clinical takeawayConsider discussing dietary MUFA intake with postmenopausal females, particularly from dairy and meat products, as part of broader CRC risk reduction strategies, though causality is not established.
What it foundDietary MUFA density was associated with a 46% higher CRC risk (HR 1.46, 95% CI 1.10-1.93) in postmenopausal U.S. females.
ContextChallenges reliance on self-reported dietary data by using serum-based biomarkers, aligning with prior evidence linking MUFA intake to CRC risk.
Measured against the standard of care· USMSTF 2017 (Rex et al., Gastroenterology) + USMSTF 2022 focused update on age (Patel et al., Gastroenterology 2022;162:285-299) / ACS 2026 (CA Cancer J Clin)

Decision at stakewhether dietary macronutrient composition influences colorectal cancer risk in postmenopausal women

… Multi-Society Task Force (2017 guideline, revised by the 2022 focused update on age to start and stop): offer average-risk colorectal cancer screening to everyone aged 45-75. … The American Cancer Society's May 2026 guideline agrees on the 45-75 range, no screening after 85, and colonoscopy as the preferred option. …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

U.S. Multi-Society Task Force (2017 guideline, revised by the 2022 focused update on age to start and stop): offer average-risk colorectal cancer screening to everyone aged 45-75. Screening at 45-49 is a weaker recommendation than at 50-75. Colonoscopy every 10 years and annual FIT are the Tier 1 cornerstones. Tier 2 alternatives are multi-target stool DNA every 3 years, CT colonography every 5 years, and flexible sigmoidoscopy every 5-10 years. Capsule colonoscopy every 5 years is Tier 3. Any abnormal non-colonoscopy test requires a diagnostic colonoscopy, and a stool test should not be offered to a patient who would decline follow-up colonoscopy. Patients who are up to date with negative prior screening, particularly a high-quality colonoscopy, may consider stopping at 75 or when life expectancy is under 10 years. Decisions at 76-85 are individualized by health and prior screening, and screening after 85 is not recommended. The American Cancer Society's May 2026 guideline agrees on the 45-75 range, no screening after 85, and colonoscopy as the preferred option. It adds the next-generation mt-sDNA test and the multitarget stool RNA test (ColoSense), both every 3 years, and it adds an FDA-approved blood-based cfDNA test (Shield) only for people who decline or do not complete visual or stool screening. ACS says a positive stool or blood test should be followed by colonoscopy, preferably within 6 months. The 2026 ASGE paper on follow-up after an abnormal stool test is an implementation review (navigation, tracking, direct-access colonoscopy), not a new screening guideline.

USMSTF 2017 (Rex et al., Gastroenterology) + USMSTF 2022 focused update on age (Patel et al., Gastroenterology 2022;162:285-299) / ACS 2026 (CA Cancer J Clin) · reviewed 2026-10-11 ↗
Prentice RL … Zheng C · American Journal of Clinical Nutrition · IF 6.5 · PubMed ↗Permalink
← Back to issue №10 Every section of this issue is one click away, at the top of this page. Follow Nutrition by RSS